Tag Archives: Bayer Healthcare

p4p_banner3

Fight Colorectal Cancer Heads to Minnesota for Pitch for Prevention

Fight Colorectal Cancer Heads to Minnesota for Pitch for Prevention

FOR IMMEDIATE RELEASE National March Against Colorectal Cancer Heads to Minnesota Twins’ Target Field for Pitch for Prevention Fight Colorectal Cancer’s coast-to-coast colorectal cancer awareness campaign, One Million Strong, is collaborating with Mayo Clinic and prostate cancer group Ed Randall’s Fans for the Cure to raise awareness of ‘below the belt’ cancers at Target Field July 18, 2014 – ALEXANDRIA, Va. – Fight Colorectal Cancer’s (Fight CRC) One Million Strong campaign, a movement creating awareness of colon and rectal cancer, will be in the Twin Cities area July 21-23 as part of the Pitch for Prevention campaign. Fight CRC will join forces with the Mayo Clinic and prostate cancer group

Time To Lace Up Your Virtual Walking Shoes

Okay – so I know that exercise is very good for colorectal cancer survivors. And I am definitely an advocate for healthy lifestyles. But I have to admit – this virtual walk that is raising money for Fight Colorectal Cancer is pretty stinking amazing. Maybe that’s because my car is covered in a foot of snow and the last thing I want to do is walk or run outside. So I am all for an opportunity to raise money simply by signing up for a virtual walk where I don’t have to fight the cold or even get up from my desk. There’s not even fundraising involved. A few clicks

Regorafenib Now Available Via Expanded Access

Click Here to Get updates from Fight Colorectal Cancer The first four sites where colorectal cancer patients can get regorafenib are now open.  Bayer Healthcare expects to open additional sites in the next two or three weeks. Colorectal cancer patients whose cancer has gotten worse on all standard treatments can now be considered for the Regorafenib Extended Access program. Bayer Healthcare has applied for FDA approval of regorafenib to treat colorectal cancer, but until it is actually approved and on the market, the expanded access program is the only way patients who might benefit can receive it. Last fall, early results from the randomized Phase 3 CORRECT clinical trial showed

Top